TherapeuticsMD Stock News

TherapeuticsMD, Inc. (NASDAQ:TXMD) Director Cooper C. Collins bought 1,000,000 shares of the company’s stock in a transaction that occurred on Thursday, November 18th. The shares were acquired at an average price of $0.58 per share, for a total transaction of $580,000.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, […]

Charles Schwab Investment Management Inc. grew its holdings in TherapeuticsMD, Inc. (NASDAQ:TXMD) by 4.2% in the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 2,488,953 shares of the companys stock after buying an additional 99,443 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately []

TherapeuticsMD, Inc. (NASDAQ:TXMD) Director Cooper C. Collins bought 1,000,000 shares of TherapeuticsMD stock in a transaction that occurred on Thursday, November 18th. The stock was bought at an average cost of $0.58 per share, for a total transaction of $580,000.00. The transaction was disclosed in a legal filing with the SEC, which is available at []

In todays recent session, 2.85 million shares of the TherapeuticsMD Inc. (NASDAQ:TXMD) have been traded, and its beta is 1.76. Most recently the companys share price was $0.59, and it changed around $0.02 or 4.05% from the last close, which brings the market valuation of the company to $248.29M. TXMD at last check was trading TherapeuticsMD Inc. (NASDAQ: TXMD): A Stock Worth Thinking About Today Read More »

The trading price of TherapeuticsMD Inc. (NASDAQ:TXMD) closed lower on Friday, November 19, closing at $0.57, -2.71% lower than its previous close. >> 7 Top Picks for the Post-Pandemic Economy

TherapeuticsMD, Inc. (TXMD) with the stream of -2.71% also noticed, India Truist Financial Corporation (TFC) encountered a rapid change of -1.99% in the last hour of Friday’s trading session. TherapeuticsMD, … The post Nano Dimension Ltd., NASDAQ:NNDM, NNDM NEWS, NNDM STOCK, Teck Resources Limited, NYSE:TECK, TECK NEWS, TECK STOCK, NNDM, TECK appeared first on Stocks Equity .

TherapeuticsMD Inc. (NASDAQ:TXMD)s traded shares stood at 5.76 million during the last session, with the companys beta value hitting 1.78. At the close of trading, the stocks price was $0.57, to imply a decrease of -2.30% or -$0.02 in intraday trading. The TXMD shares 52-week high remains $2.75, putting it -382.46% down since that peak TherapeuticsMD Inc. (NASDAQ:TXMD) Down -1.75% Since 52-Week Low; YTD Fall -52.52% Heres What You Need To Do Read More »

In the latest trading session, 3.25 million TherapeuticsMD Inc. (NASDAQ:TXMD) shares changed hands as the companys beta touched 1.78. With the companys most recent per share price at $0.60 changed hands at -$0.03 or -4.48% at last look, the market valuation stands at $279.79M. TXMDs current price is a discount, trading about -358.33% off its TherapeuticsMD Inc. (NASDAQ: TXMD): Why Investors Shouldnt Ditch TXMD Stock In 2021 Read More »

TherapeuticsMD, Inc. (TXMD) CEO Rob Finizio on Q3 2021 Earnings Conference Call - Earnings Call Transcript

TherapeuticsMD (NASDAQ:TXMD) reported its Q3 earnings results on Thursday, November 11, 2021 at 08:00 AM. Here's what investors need to know about the announcement.

Are these Webull penny stocks to buy or avoid right now? The post 5 Penny Stocks To Buy For Under $1 On Webull Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStock

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NASDAQ: TXMD) (“TXMD” or the “Company”), an innovative, leading women's healthcare company, today announced that it will report its thi

Despite having an impressive product portfolio and established commercial organization, the company has struggled to get their products off the launchpad and through COVID-19 headwinds.

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women's healthcare company, today announced the appointment of Mark Glickman as the Company's Chief Busin

LONDON--(BUSINESS WIRE)--Theramex launches Bijuva® (estradiol and progesterone), the first and only body-identical combined hormone therapy treatment for post-menopausal women